

Invesco Nasdaq Biotechnology ETF

As of December 31, 2022



Fund description

The Invesco Nasdaq Biotechnology ETF (Fund) is based on the Nasdaq Biotechnology Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The Fund and the Index are reconstituted annually in December and rebalanced quarterly in March, June, September and December.

Effective from the Fund's inception on Jun. 11, 2021 through Dec. 17, 2021, Invesco Capital Management LLC (the "Adviser") will waive 100% of its management fee, 0.19%, for the Fund. The Net Expense Ratio for the Fund through December 17, 2021 is 0.00%.

ETF Information


| | |
|-------------------------------|----------------------------------|
| Fund Name | Invesco Nasdaq Biotechnology ETF |
| Fund Ticker | IBBQ |
| CUSIP | 46138G599 |
| Intraday NAV | N/A |
| 30 Day SEC Unsubsidized Yield | 0.56% |
| 30 day SEC Yield | 0.56% |
| Holdings | 273 |
| Management Fee | 0.19% |
| Total Expense Ratio | 0.19% |
| P/B Ratio | 6.49 |
| P/E Ratio | 4.65 |
| Return on Equity | 0.72% |
| Listing Exchange | Nasdaq |
| Weighted Market Cap (\$MM) | 52,395.48 |

Underlying Index Data

| | |
|----------------|----------------------------------|
| Index Provider | Nasdaq, Inc. |
| Index Name | Nasdaq Biotechnology Index (USD) |
| Index Ticker | XNBI |

Growth of \$10,000

- Invesco Nasdaq Biotechnology ETF: \$8,367
- Nasdaq Biotechnology Index (USD): \$8,377
- S&P Composite 1500 Biotechnology Index (USD): \$11,419



Data beginning Fund Inception and ending December 31, 2022. Fund performance shown at NAV.

Performance as at December 31, 2022

| Performance (%) | YTD | 1Y | 3Y | 5Y | 10Y | Fund Inception |
|------------------------|--------|--------|-------|------|-------|----------------|
| ETF - NAV | -10.24 | -10.24 | - | - | - | -10.85 |
| ETF - Market Price | -10.36 | -10.36 | - | - | - | -10.88 |
| Underlying Index | -10.12 | -10.12 | 4.36 | 5.32 | 11.95 | -10.78 |
| Benchmark ¹ | 13.68 | 13.68 | 11.46 | 8.94 | 14.64 | 8.92 |

Calendar year performance (%)

| | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|------------------------|--------|------|------|------|------|------|------|------|------|------|
| ETF - NAV | -10.24 | - | - | - | - | - | - | - | - | - |
| Underlying Index | -10.12 | - | - | - | - | - | - | - | - | - |
| Benchmark ¹ | 13.68 | - | - | - | - | - | - | - | - | - |

Returns less than one year are cumulative. Performance data quoted represents past performance. Past performance is not a guarantee of future results; current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and Shares, when redeemed, may be worth more or less than their original cost. See [invesco.com](https://www.invesco.com) to find the most recent month-end performance numbers. Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Please keep in mind that high, double-digit and/or triple-digit returns are highly unusual and cannot be sustained.

Fund inception: June 11, 2021

Not a Deposit Not FDIC Insured Not Guaranteed by the Bank May Lose Value Not Insured by any Federal Government Agency


Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 10,000 Shares.

Index returns do not represent Fund returns. An investor cannot invest directly in an index. Neither the underlying Index nor the benchmark indexes charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown; nor do any of the indexes lend securities, and no revenues from securities lending were added to the performance shown. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in the Fund. ¹S&P Composite 1500 Biotechnology Index Consists of all Biotechnology stocks including in the S&P Composite 1500 Index.

| Top ETF holdings (%) | | (Total holdings: 273) |
|---------------------------|--------|-----------------------|
| Name | Weight | |
| Gilead Sciences | 8.06 | |
| Amgen | 7.56 | |
| Regeneron Pharmaceuticals | 7.30 | |
| Vertex Pharmaceuticals | 7.00 | |
| Moderna | 6.52 | |
| AstraZeneca ADR | 3.91 | |
| Biogen | 3.74 | |
| Illumina | 3.01 | |
| Alnylam Pharmaceuticals | 2.76 | |
| Horizon Therapeutics | 2.44 | |


Please see the website for complete holdings information. Holdings are subject to change.

Geographic allocation (%)



| | |
|----------------|-------|
| United States | 87.98 |
| United Kingdom | 4.36 |
| Germany | 1.47 |
| France | 1.32 |
| China | 1.28 |
| Netherlands | 1.28 |
| Denmark | 0.82 |
| Canada | 0.72 |
| Ireland | 0.32 |
| Switzerland | 0.30 |

Sector allocation (%)



| | |
|--------------------------------|-------|
| Biotechnology | 80.51 |
| Pharmaceuticals | 13.45 |
| Life Sciences Tools & Services | 4.88 |
| Health Care Equipment | 0.76 |
| Health Care Services | 0.38 |
| Health Care Distributors | 0.03 |

Investment risks

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund's return may not match the return of the Underlying Index. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

The Fund is non-diversified and may experience greater volatility than a more diversified investment.

Investments focused in a particular industry, such as biotechnology, are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.

Important information

Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.

The Global Industry Classification Standards was developed by and is the exclusive property and a service mark of MSCI, Inc. and Standard & Poor's.

The Invesco Nasdaq Biotechnology ETF is not sponsored, endorsed, sold or promoted by the NASDAQ OMX Group, Inc. or its affiliates (NASDAQ OMX, with its affiliates, are referred to as the "Corporations"). The Corporations have no liability in connection with the administration, marketing or trading of the Invesco Nasdaq Biotechnology ETF. "NASDAQ®" is a registered trademark and is used under license.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

Invesco Capital Management LLC, investment adviser and Invesco Distributors, Inc., ETF distributor, are indirect, wholly owned subsidiaries of Invesco Ltd.

Before investing, investors should carefully read the prospectus and consider the investment objectives, risks, charges and expenses. For this and more complete information about the fund, investors should ask their financial professionals for a prospectus or download one at invesco.com

Note: Not all products available through all firms or in all jurisdictions.

Glossary

30 Day SEC Unsubsidized Yield reflects the 30-day yield if the investment adviser were not waiving all or part of its fee or reimbursing the fund for part of its expenses. Total return would have also been lower in the absence of these temporary reimbursements or waivers.

30 Day SEC Yield is based on a 30-day period and is computed by dividing the net investment income per share earned during the period by the maximum offering price per share on the last day of the period.

Intraday NAV is a symbol representing estimated fair value based on the most recent intraday price of underlying assets.

Weighted Harmonic Average Stock Price-to-Book-Value Ratio (P/B Ratio) is the ratio of a stock's market price to a company's net asset value.

Weighted Harmonic Average Stock Price-to-Earnings Ratio (P/E Ratio) is the share price divided by earnings per share. It is measured on a 12-month trailing basis.

Weighted Average Return on Equity is net income divided by net worth.

Weighted Market Capitalization is the sum of each underlying securities market value.